3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
52
Carcinoma, Renal Cell
47
Neoplasm Metastasis
24
Neoplasms
18
Kidney Neoplasms
18
Neuroendocrine Tumors
17
Carcinoma, Non-Small-Cell Lung
13
Tuberous Sclerosis
12
Stomach Neoplasms
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Recurrence
10
Prostatic Neoplasms
10
Lymphoma
10
Hodgkin Disease
10
Glioblastoma
10
Colorectal Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Brain Neoplasms
9
Lymphoma, Follicular
8
Lung Neoplasms
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Carcinoma
8
Waldenstrom Macroglobulinemia
7
Triple Negative Breast Neoplasms
7
Sarcoma
7
Multiple Myeloma
7
Lymphoma, B-Cell, Marginal Zone
7
Glioma
7
Central Nervous System Neoplasms
7
Interventions
Cannabidiol
3
perampanel
2
Tranexamic Acid
2
Levetiracetam
2
ziprasidone
1
enzalutamide
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tobramycin
1
Standard of Care
1
Spironolactone
1
Sodium Chloride
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Remifentanil
1
Propofol
1
Pregabalin
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Methylprednisolone
1
Mental Status and Dementia Tests
1
Magnetic Resonance Spectroscopy
1
Magnesium Sulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Seizures
×
Everolimus
×
Clear all
NCT00790400
2017-02-17
EXIST-2
Novartis
Phase 3
Completed
118 enrolled
15 charts